Maternally sequestered therapeutic polypeptides â€“ a new approach for the management of preeclampsia by Gene L. Bidwell & Eric M. George
HYPOTHESIS AND THEORY ARTICLE
published: 05 September 2014
doi: 10.3389/fphar.2014.00201
Maternally sequestered therapeutic polypeptides – a new
approach for the management of preeclampsia
Gene L. Bidwell III 1,2 and Eric M. George 2,3*
1 Department of Neurology, The University of Mississippi Medical Center, Jackson, MS, USA
2 Department of Biochemistry, The University of Mississippi Medical Center, Jackson, MS, USA
3 Department of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, MS, USA
Edited by:
Carlos Alonso Escudero, Universidad
del Bio-Bio, Chile
Reviewed by:
Siu-Lung Chan, University of Vermont,
USA
Marie Van Dijk, VU University Medical
Center, Netherlands
Carlos Alonso Escudero, Universidad
del Bio-Bio, Chile
*Correspondence:
Eric M. George, Department of
Physiology and Biophysics, The
University of Mississippi Medical
Center, 2500 North State Street,
Jackson, MS 39216, USA
e-mail: egeorge@umc.edu
The last several decades have seen intensive research into the molecular mechanisms
underlying the symptoms of preeclampsia. While the underlying cause of preeclampsia
is believed to be defective placental development and resulting placental ischemia, it is
only recently that the links between the ischemic placenta and maternal symptomatic
manifestation have been elucidated. Several different pathways have been implicated in
the development of the disorder; most notably production of the anti-angiogenic protein
sFlt-1, induction of auto-immunity and inﬂammation, and production of reactive oxygen
species.While themolecularmechanisms are becoming clearer, translating that knowledge
into effective therapeutics has proven elusive. Herewe describe a number of peptide based
therapies we have developed to target theses pathways, and which are currently being
tested in preclinical models.These therapeutics are based on a synthetic polymeric carrier
elastin-like polypeptide (ELP), which can be synthesized in various sequences and sizes to
stabilize the therapeutic peptide and avoid crossing the placental interface. This prevents
fetal exposure and potential developmental effects. The therapeutics designed will target
known pathogenic pathways, and the ELP carrier could prove to be a versatile delivery
system for administration of a variety of therapeutics during pregnancy.
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INTRODUCTION
One of the most common complications encountered in obstet-
rical practice is preeclampsia, occurring in ∼5% of all gestations.
Preeclampsia was classically deﬁned as new-onset hypertension
and proteinuria, but recent diagnostic criteria released from the
American Congress of Obstetricians and Gynecologists (ACOG)
has recognized that proteinuria is one of many possible diagnos-
tic criteria (thrombocytopenia, renal insufﬁciency, impaired liver
function, pulmonary edema, or cerebral/visual symptoms) which,
when manifested in combination with hypertension, indicate a
preeclampsia diagnosis (American College of Obstetricians and
Gynecologists and Task Force on Hypertension, 2013). Frustrat-
ingly, there is little in the way of pharmacological intervention at
thedisposal of thephysician for themanagementof thepreeclamp-
sia patient, and the only deﬁnitive resolution of the disorder is
parturition. Current management of these patients is limited to
magnesium sulfate for seizure prophylaxis, bed rest, and admin-
istration of various anti-hypertensives which typically fail to fully
control the progressing hypertension. Unchecked, preeclampsia
can potentially develop into eclampsia, which leads to seizures and
in some cases, death. Development of new therapeutics for the
management of the preeclampsia patient remains an important
area of research in obstetrics.
While a great deal of research has begun to elucidate the
molecular and physiological mechanisms which are responsible
for the maternal symptoms, the initiating causes remain unclear.
What has become generally accepted is that the disorder is closely
linked to defects at the maternal/fetal interface, particularly in the
remodeling of the maternal spiral arteries which supply the blood
ﬂow to the placenta (Khong and Brosens, 2011). During gestation,
the developing fetus requires copious amounts of blood ﬂow to the
placenta to allow for adequate exchange of nutrients and wastes
between the maternal and fetal circulations. To ensure adequate
delivery of blood, thematernal spiral arteries of the uterus undergo
a dramatic remodeling. Fetally derived cytotrophoblasts invade
the maternal vessels, displace the endothelium, and convert the
normally small diameter, low capacitance vessels into dilated high
capacitance vessels. Clues that the placenta was central to the etiol-
ogy of preeclampsia came from case reports showing that delivery
of the fetus alone was insufﬁcient to remit the disease symptoms,
and that delivery of the placenta was crucial for resolution (Shem-
brey andNoble, 1995). Early histological examination of placentas
from preeclampsia patients suggested that the remodeling of these
arteries in preeclampsia patients was deﬁcient, with only very
shallow trophoblast invasion and arterial remodeling. This led
to the idea that in preeclampsia, the placenta-which even in nor-
mal pregnancy is relatively hypoxic-receives inadequate blood ﬂow
and in consequence experiences chronic hypoxia and ischemia.
Indeed, a host of studies over the last 15 years have strongly impli-
cated placental ischemia as a central factor in the manifestation of
preeclampsia. Research into the molecular links between chronic
placental ischemia and the symptomatic phase of the disorder
continue, but several pathways have been intensively investigated
and validated. This includes production of the anti-angiogenic
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protein soluble fms-like tyrosine kinase-1 (sFlt-1), production
of inﬂammatory cytokines such as TNFα, and increased produc-
tion of oxidative stress in the placenta and maternal vasculature
(Figure 1).
PATHWAYS DRIVING PREECLAMPSIA
ANGIOGENIC IMBALANCE
One of the pivotal breakthroughs in the understanding of
preeclampsia was the recognition of increased circulating lev-
els of the vascular endothelial growth factor (VEGF) antagonist
sFlt-1 in the circulation of preeclampsia patients (Maynard et al.,
2003). sFlt-1 is a soluble, alternatively transcribed isoform of the
VEGF receptor Flt-1 and consists only of the receptor’s recogni-
tion domain. This soluble protein is then secreted extracellularly,
where it competes for VEGF binding, thus making VEGF unavail-
able to bind to its full length, active receptors (Wu et al., 2010).
While themechanismswhich regulate sFlt-1 splicing are still under
investigation, a number of preclinical studies have shown that
production of sFlt-1 from placental tissue is increased by either
in vivo chronic ischemia, or acutely by hypoxia ex vivo (Ahmad
and Ahmed, 2004; Nagamatsu et al., 2004; Nevo et al., 2006;
George et al., 2010).
FIGURE 1 |The maternal symptoms of preeclampsia arise through
multiple molecular mechanisms. Improper placentation leads to
placental ischemia. As a direct result, the placenta produces the
anti-angiogenic protein sFlt-1, inﬂammatory cytokines, and increased
reactive oxygen species (ROS); as well as increased production of the
agonistic AT-1 receptor autoantibody (AT1-AA). The maternal vasculature,
including that in the kidneys, is exposed to decreased VEGF signaling and
inﬂammatory mechanisms which cause endothelial dysfunction, marked by
overproduction of the vasoconstrictor endothelin-1 (ET-1). In the kidneys,
total peripheral resistance (TPR) increases, renal blood ﬂow (RBF) and
glomerular ﬁltration rate (GFR) decrease, and maternal hypertension is the
end result.
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A variety of studies have supported a link between loss of
VEGF activity and hypertension. Patients receiving the anti-VEGF
antibody therapy bevacizumab experience hypertension and pro-
teinuria – side effectswhich are remarkably similar to preeclampsia
patients (Zhu et al., 2007). Likewise, inhibition of theVEGF recep-
tors by small molecule tyrosine kinase inhibitors increases blood
pressure, at least partially mediated by increased endothelin-1
expression – a known ﬁnal effector of hypertension in preeclamp-
sia patients (Kappers et al., 2010, 2011, 2012; George and Granger,
2011). Finally, a plethora of studies have demonstrated that
increasing circulating sFlt-1 levels through direct administration
or viral overexpression induces a hypertensive, preeclampsia-like
phenotype in animal models (Maynard et al., 2003; Li et al., 2007;
Bridges et al., 2009; Suzuki et al., 2009; Gilbert et al., 2010; Murphy
et al., 2010). sFlt-1 has therefore become a major target of interest,
and a recent study has shown beneﬁcial effects of sFlt-1 removal
by apheresis in a small cohort of preeclampsia patients (Thadhani
et al., 2011). Therapeutics targeting sFlt-1 to restore angiogenic
balance are a promising avenue for drug development.
THE MATERNAL INFLAMMATORY RESPONSE
Another well-characterized mechanism which has been exten-
sively studied is the production of inﬂammatory cytokines in
response to placental ischemia/hypoxia. Recent research has
revealed that inﬂammatory processes play an important role in
the etiology and progression of preeclampsia (Borzychowski et al.,
2006; Ahn et al., 2011). The placenta is home to a variety of
hematopoietic cells, including T cells, natural killer (NK) cells,
and macrophages, and all have roles in production of cytokines
including TNF-α and pro-inﬂammatory interleukins that exacer-
bate the immune response in preeclampsia (Azizieh et al., 2005).
This highly inﬂammatory environment is a double-edged sword.
High INF-γ and TNF-α levels inhibit trophoblast migration and
are directly toxic to trophoblasts (Yui et al., 1994; Todt et al., 1996;
Rasmussen et al., 1999), so they may contribute to the initial
improper remodeling that leads to preeclampsia. Also, TNF-
α and other inﬂammatory factors induce systemic endothelial
dysfunction, including increased endothelin-1 release, induction
of oxidative stress, and enhanced sensitivity to angiotensin II
(AngII), which combine to exacerbate the maternal hypertension
(Gilbert et al., 2008).
Of all the inﬂammatory cytokines examined, perhaps none
have been as consistently described and characterized as TNF-
α. Elevated TNF-α levels have been described in both the
maternal circulation and amniotic ﬂuid of preeclampsia patients
(Kupferminc et al., 1994; Vince et al., 1995) as well as in the pla-
centa and circulation of rodents undergoing placental ischemia
(LaMarca et al., 2008). In rats, blockade of TNF-α signaling by
etanercept partially attenuates the hypertension associated with
placental ischemia, and infusion of TNF-α to levels seen in
rodents with placental ischemia leads to a hypertensive phenotype
associated with increased vascular production of endothelin-
1 (LaMarca et al., 2005, 2008). Furthermore, one of the most
recently elucidated pathways in preeclampsia is the production
of agonistic auto-antibodies to the angiotensin type 1 receptor
(AT1-AA) which are found in a large percentage of preeclamp-
sia patients (Xia et al., 2003; Herse et al., 2009). Interestingly,
the AT1-AA has been shown to induce the production of
TNF-α in pregnant mice, suggesting that it might be one of
the upstream regulators of TNF-α production in preeclamp-
sia patients (Irani et al., 2010). These data and others suggest
that TNF-α is an important regulator of the symptoms associ-
ated with preeclampsia and placental ischemia. Targeting of the
inﬂammatory cascade set off by increased TNF-α levels could
be an important target in the development of preeclampsia
therapeutics.
OXIDATIVE STRESS
One other known player in the response to placental ischemia is
the production of reactive oxygen species (ROS). The ischemic
environment of the preeclamptic placenta has been shown to
induce ROS production, (Staff et al., 1999a,b) either as a direct
consequence of hypoxia or as a secondary response to the local
inﬂammatory environment. Additionally, ROS production may
also be induced in the systemic vasculature due to the highly
inﬂammatory environment (Roggensack et al., 1999). Superox-
ide is the major ROS produced in the preeclamptic placenta, and
its production might be a consequence of the action of the mito-
chondrial electron transport chain enzymes, xanthine oxidase, or
NADPH oxidase (Nox) operating under low oxygen conditions
(Myatt, 2010). Superoxide can act locally as a damaging oxidant, it
can dismute to hydrogen peroxide, or it can react with nitric oxide
to produce peroxynitrite (Myatt, 2010).
The increase in ROS in both the placenta and in the systemic
vasculature might play a role in the development of PE symp-
toms.Within the placenta, superoxide and peroxynitrite act locally
at the site of production in the vascular endothelium and sur-
rounding stroma to induce damaging protein oxidation, lipid
peroxidation, or protein nitration (Myatt, 2010). Systemically,
ROS (produced by neutrophils (Lee et al., 2003a,b) or directly
in vascular endothelial cells) can further exacerbate endothelial
dysfunction, leading to endothelin-1 production and reduced NO
bioavailability, which ultimately lead to hypertension via increased
total peripheral resistance (TPR; George and Granger, 2011). In
addition to the direct induction of ROS production in the placenta
and the systemic vasculature, women with PE also have decreased
superoxide dismutase (SOD), glutathione, and glutathione perox-
idase levels and impaired SOD activity (Wang and Walsh, 2001).
Therefore, they may have a reduced antioxidant capacity and
thus a heightened response to the ROS production relative to
a normal pregnant mother (Myatt and Cui, 2004). Supporting
ROS as a target for intervention, rats with hypertension result-
ing from placental ischemia or sFlt-1 excess have signiﬁcantly
decreased blood pressure when administered anti-oxidant com-
pounds (Sedeek et al., 2008; Tam Tam et al., 2011). These data
suggest that ROS is a major contributor to the symptomatic man-
ifestation of preeclampsia and that target modulation of ROS
could be a potential therapeutic approach for the preeclampsia
patient.
THERAPEUTIC STRATEGIES TARGETING THE MECHANISMS
DRIVING HYPERTENSION IN PREECLAMPSIA
Above, we have outlined the evidence supporting ischemia-
induced placental production of sFlt-1, activation of the innate
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immune system, and induction of ROS production in the symp-
tomatic manifestation of preeclampsia. Elucidation of these
pathways that clearly drive the symptomatic phase of the disease
lead us to hypothesize that interventions targeted to these path-
ways could be effective therapies for preeclampsia. Speciﬁcally, we
hypothesize that supplementation with exogenous VEGF or pla-
cental growth factor (PlGF) to restore the depressed levels and
sequester the overabundant sFlt-1 will have a positive effect on
maternal hypertension, and as a result, fetal health both at birth
and later in life. Similarly, we hypothesize that inhibition of the
inﬂammatory pathway by inhibition of its mastermediator NF-κB
will serve to improve bothmaternal symptoms and fetal outcomes.
Finally, we suggest that selective inhibition of enzymes responsible
for ROS production could be beneﬁcial for PE therapy. How-
ever, in order to achieve these outcomes, novel sFlt-1, NF-κB, and
ROS inhibiting agents must be stabilized from degradation in the
maternal circulation and ideally be prevented from crossing the
placental interface and entering the fetal circulation, where they
could be harmful to the developing fetus.
THE ELP DRUG DELIVERY SYSTEM
Our group has recently been developing a carrier protein called
elastin-like polypeptide (ELP) for use as a drug delivery vector
during pregnancy. ELP is a genetically engineered polypeptide
consisting of repeated units of a ﬁve amino-acid motif (VPGxG,
where x is any amino acid except P; Urry et al., 1991a). ELP has
a unique property of reversibly forming aggregates in response to
heat. Above a characteristic transition temperature, the polypep-
tide will form aggregates, and when the solution is lowered below
the transition temperature, the aggregates re-dissolve (Urry et al.,
1991a). There are several advantages of using ELP polypeptides
for drug delivery. First, ELPs are genetically encoded rather than
chemically synthesized. The coding sequence for ELP is built into
a plasmid-based recombinant expression system. This means the
researcher has absolute control over the ELP sequence and molec-
ular weight (MW). Changes to the ELP sequence or modiﬁcation
of the number of ELP repeats are achieved by simple molecular
biology techniques. This is important because the size of a polymer
carrier inﬂuences the plasma pharmacokinetics and tissue distri-
bution (Dreher et al., 2006), and because the size and sequence
of ELP inﬂuences the transition temperature of its heat-induced
aggregation (Urry et al., 1991a). Also, addition of targeting pep-
tides and therapeutic proteins is easily achieved by modifying the
DNA coding sequence. Second, ELP and ELP-fusion proteins can
be expressed in E. coli, and large quantities of the molecules can
be puriﬁed by simply taking advantage of the thermal responsive-
ness. Puriﬁcation of ELP-fusion proteins is achieved by heating
a bacterial lysate containing the recombinantly expressed ELP
to a temperature above the polypeptides’ transition temperature.
This induces ELP aggregation, and it is collected by centrifugation
(Meyer and Chilkoti, 1999; Bidwell and Raucher, 2005). Repeated
centrifugation above and below the transition temperature leads
to large quantities of very pure protein (Meyer and Chilkoti, 1999;
Bidwell and Raucher, 2005). The third advantage for using ELP
for drug delivery is that it is a large, biologically inert macro-
molecule. Therefore, ELP fusion can stabilize protein, peptide, or
small molecule cargo in systemic circulation (Bidwell et al., 2012,
2013), and targeting agents can be used to direct the ELP-fused
therapeutics’ biodistribution (Bidwell et al., 2009). Previous work
has used ELPs extensively for drug delivery in cancer models.
These studies have carefully deﬁned the polypeptide’s pharma-
cokinetics and biodistribution (Liu et al., 2006; Bidwell et al., 2012,
2013; Moktan et al., 2012), conﬁrming ELP as a long circulating,
inert, biodegradable, and non-immunogenic (Urry et al., 1991b)
drug carrier. In addition, our previous cancer work also serves as
proof of principle for the ability to ELP to efﬁcaciously deliver
active therapeutic peptides (Bidwell et al., 2012, 2013). Recently,
we have found that ELP has a long half-life after intravenous injec-
tion in a rat pregnancy model, but importantly, ELP does not
cross the placenta (George et al., 2014). Our current goals are to
leverage this powerful delivery system to (1) stabilize therapeutic
proteins, peptides, or small molecules targeted to preeclampsia
mechanisms in the maternal circulation and (2) prevent the pen-
etration of these therapeutic agents into the developing fetus. We
are currently developing ELP-fused therapeutics to target all three
pathways described above using ELP-fused toVEGF or PlGF, ELP-
fused peptide inhibitors of NF-κB, and peptide inhibitors of NOX
(Figure 2).
The ELP delivery system can be utilized in either an untar-
geted manner, which is useful when attached to agents designed
to circulate, or it can be targeted to enter cells or even to spe-
ciﬁc intracellular compartments using cell penetrating peptides
(CPPs; Massodi et al., 2005; Bidwell et al., 2009). CPPs do not
necessarily provide tissue speciﬁcity, but they do enhance depo-
sition of ELP in many of the major organs, most notably the
kidney (Bidwell et al., 2013). For delivery of VEGF or PlGF, we
are utilizing a version of the polypeptide that is untargeted. This
will allow the ELP-VEGF or ELP-PlGF to freely circulate, where
it can bind and sequester the excess s-Flt-1. For delivery of the
NF-κB inhibitory peptides or the NOX inhibitory peptides (which
have intracellular targets), we are utilizing ELP vectors fused to
CPPs to mediate cellular uptake of the polypeptide and direct
them to the cytoplasm. We have previously shown that mul-
tiple CPPs are effective for intracellular delivery of ELP both
in vitro (Massodi et al., 2005) and in vivo (Bidwell et al., 2012,
2013; Moktan et al., 2012).
In a recent study, we demonstrated that ELP and a CPP-tagged
ELP are excluded from the fetus after systemic administration to
the mother in a rat pregnancy model (George et al., 2014). Fur-
thermore, this fetal exclusion held even after 5 days of continuous
infusion of the polypeptides. Within the placenta, both ELP and
CPP-tagged ELP were detectable in the cytoplasm of trophoblast
cells, but were absent from the fetal portion of chorionic villi. We
believe that the size of the ELPs prevents them from crossing the
tight junctions between trophoblast cells in the chorionic villi.
NOVEL THERAPIES TARGETING THE sFlt-1/VEGF PATHWAY
As described above, one of the hallmarks of preeclampsia is the
elevated maternal plasma levels of the VEGF antagonist sFlt-1.We
hypothesize that VEGF or PlGF supplementation therapy could
be a viable mechanism to sequester the excess sFlt-1 and thereby
prevent or reverse the onset of hypertension.While we believe that
VEGF supplementation therapy will be beneﬁcial for treatment of
preeclampsia, the therapeutic strategy is not as straightforward as
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FIGURE 2 | Potential sites of intervention with maternally restricted
therapeutic peptides during preeclampsia.We have recently produced
several novel maternally restricted peptide therapeutics to target known
pathologic molecules produced in response to placental ischemia in
preeclampsia. Much of the activity of inﬂammatory cytokines is through the
master regulator NF-κB, which could be blocked by the inhibitory ELP-p50
peptide which blocks nuclear translocation of NF-κB, a transcription factor. The
major source of oxidative stress in the ischemic placenta is the NADPH
oxidase (Nox) enzyme, which could be inhibited by the Nox inhibitory peptide,
which blocks assembly of the complete complex. Finally, one of the most
extensively characterized mechanisms is production of the VEGF inhibitor
sFlt-1, which act as a decoy receptor. Introduction of ELP-stabilized VEGF or
PlGF fusions would restore VEGF signaling by their direct activity, and/or by
sequestering the excess sFlt-1 in the maternal circulation. Ultimately all of
these proposed peptides help to restore endothelial function and renal
function to block the maternal hypertension.
simply infusing VEGF. VEGF infusions have been tested in sev-
eral disease models, and this approach has been hindered by many
problems. First, free exogenous VEGF is very short-lived, with a
plasma half-life in humans of about 34 min (as determined fol-
lowing a four hour intravenous infusion of recombinant human
VEGF165; Eppler et al., 2002). ExogenousVEGF therapy has shown
potential in several disease models, including myocardial infarc-
tion (Banai et al., 1994; Pearlman et al., 1995), but due to the short
half-life and poor stability of the protein, constant infusion via
a pump-driven catheter placed directly at the diseased site was
required. This type of treatment strategy is not a viable transla-
tional approach for preeclampsia therapy, where patients will need
to be treated for several months.
The second limitation of free VEGF supplementation for
preeclampsia therapy involves its potential for damage to the
developing fetus. Several reports have demonstrated the severe
potential consequences of overloading the fetus with VEGF. Over-
expression of VEGF-A by two to threefold using a genetic strategy
in mouse embryos resulted in embryonic lethality at day E12.5
(Miquerol et al., 2000). Death was due to cardiac failure resulting
frommalformation of themyocardium, improper ventricular sep-
tation, and abnormalities in the heart’s outﬂow track. A separate
study in which quail embryos were directly injected with exoge-
nous VEGF showed similar results. The VEGF treated embryos
had neovascularization in normally avascular regions and exces-
sive, improper fusion of vessels (Drake and Little, 1995). Like the
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mouse study, these VEGF treated embryos also had malforma-
tion of the hearts, including fusion of inﬂow and aortic outﬂow
channels. These studies address the dire consequences of increas-
ing VEGF levels directly in the developing fetus, but it has also
been shown that administration of free VEGF to pregnant mice
causes developmental problems in the embryos. Daily systemic
injection of recombinant human VEGF from gestational day 9–
day 17 resulted in an 18-fold increase in the fetal reabsorption
rate and a signiﬁcant decrease in fetal weight among the surviving
fetuses (He et al., 1999). Given the limitations of short half-life
and the potential for teratogenic effects of free VEGF, we have
fused VEGF (or similarly PlGF) to the ELP carrier to both extend
its plasma half-life and prevent its delivery across the placenta.
The goal of this strategy is to supplement circulating VEGF or
PlGF levels in order to achieve levels present in normal preg-
nancy. We have recently characterized the ELP-VEGF polypeptide
and found that ELP-VEGF is equally potent at stimulating vas-
cular endothelial cell proliferation, migration through a collagen
matrix, and tube formation when compared to unbound VEGF
(unpublished data). Given the favorable biodistribution proﬁle
of ELP-fused VEGF or PlGF and a careful dosing strategy to
achieve proper VEGF or PlGF replacement, we believe that this
approach represents a promising new method for preeclampsia
therapy.
NOVEL THERAPIES TARGETING THE INFLAMMATORY PATHWAY
Many pro-inﬂammatory cytokines such as TNF-α, IL-1, and
toll like receptors (TLRs, whose signaling has also been impli-
cated in PE (Keelan and Mitchell, 2007; Tinsley et al., 2009;
Chatterjee et al., 2012) exert their effects via receptor-mediated
signaling pathways that are centrally routed through NF-κB. In
fact, NF-κB is a master regulator of inﬂammation (Makarov,
2001). For this reason combined with the multitude of inﬂam-
matory factors at play, we chose to target NF-κB as a means to
inhibit the inﬂammation associated with preeclampsia. Several
previous studies have highlighted the importance of NF-κB acti-
vation in preeclampsia. Hypoxia and reoxygenation of villous
explants leads to activation of the NF-κB pathway (Cindrova-
Davies et al., 2007), and NF-κB activation plays an important role
in the systemic endothelial dysfunction present in preeclampsia
(Jiang et al., 2010). Furthermore, analysis of microarray data of
placental tissue from preeclamptic women versus at-risk but non-
preeclamptic controls reveals NF-κB as a major pathway that is
upregulated in preeclampsia (Centlow et al., 2011).Within the pla-
centa, NF-κB levels in preeclampsia are associated with increased
trophoblast apoptosis (Aban et al., 2004), and systemic NF-κB
activation is also present in the vasculature of preeclamptic moth-
ers (Shah and Walsh, 2007). Systemic vascular NF-κB activation
is associated with neutrophil inﬁltration, and these neutrophils
release toxic substances such as TNF-α, ROS, and thrombox-
ane, which promote vasoconstriction and vascular dysfunction
(Shah and Walsh, 2007).
NF-κB activation is a complex pathway involving trimeriza-
tion of NEMO, the regulatory domain of inhibitor of κ-B kinase
(IKK), phosphorylation and deactivation of the NF-κB inhibitor
I-κB by IKK, NF-κB phosphorylation on the p65 subunit, and
active import of NF-κB into the nucleus (reviewed in Bidwell
and Raucher, 2009). Extensive interest in developing NF-κB
inhibitors exists in the cancer ﬁeld, and several previous stud-
ies have described peptide inhibitors of all the activation steps
mentioned above (Bidwell and Raucher, 2009). We have devel-
oped an ELP-fused peptide inhibitor of activated NF-κB. NF-κB
activation upon extracellular signaling is mediated by phospho-
rylation and release of the natural inhibitor I-κB from the NF-κB
p50/p65 heterodimer. I-κB release exposes a nuclear localization
sequence (NLS) on the p50 subunit of NF-κB, and once exposed,
this NLS mediates nuclear import of NF-κB. Once inside the
nucleus, NF-κB binds to response elements on its target genes
and regulates gene expression. A synthetic cell permeable peptide
containing the p50 NLS is capable of blocking the nuclear import
of NF-κB upon stimulation in a variety of cell lines (Lin et al.,
1995). We have fused a copy of the p50 NLS to the CPP-ELP car-
rier and validated its activity in vitro. We are currently focusing
on determining the pharmacokinetics and biodistribution of this
NF-κB inhibitory polypeptide, and assessing its efﬁcacy in our
rat models of PE. Initial biodistribution data have shown that the
CPP-ELP-delivered p50 NLS peptide accumulates highly in the
kidneys and the placenta. This biodistribution is advantageous
because these two organs are the most critical for modulating
the drivers of hypertension and proteinuria in preeclampsia. We
hypothesize that the polypeptide will function to inhibit NF-
κB in these tissues (either in the tissue stromal cells directly
or in invading lymphocytes) and reduce the local inﬂammatory
environment.
NOVEL THERAPIES TARGETING REACTIVE OXYGEN SPECIES
PRODUCTION
Of the possible sources listed above, the Nox family is thought
to be the major contributor to ROS production in the placenta.
Nox1 expression has been found in syncytiotrophoblasts and
vascular endothelial cells in the placenta (Matsubara and Sato,
2001; Cui et al., 2006), and its levels are enhanced in tissue from
PE patients (Cui et al., 2006). Elevated total Nox activity has
also been seen in placentas from women with early onset PE,
though no difference was seen when comparing all PE patients
to normal pregnant controls (Raijmakers et al., 2004). It has also
been demonstrated that ROS are produced via Nox2 in vascular
smooth muscle cells and trophoblasts in response to the AT1-
AA, and ROS production induced NF-κB activation (Dechend
et al., 2003). The AT1-AA also induced Nox2 subunit produc-
tion and ROS production in pregnant rats (Parrish et al., 2011).
Furthermore, treatment of vascular endothelial cells with sera
from preeclampsia patients induced production of the Nox2,
an effect attenuated by an Ang II type 1 receptor antagonist
(Matsubara et al., 2010).
We hypothesize that Nox inhibition could be a viable therapeu-
tic strategy for PE, either alone or in combination with targeting
other pathways. Patrick Pagano’s lab has described a number of
peptide inhibitors of the Nox family (reviewed in (Cifuentes-
Pagano et al., 2012). The most speciﬁc and widely used agent,
called Nox2 docking sequence (Nox2ds) or gp91ds, is an nine
amino acid peptide that inhibits the interaction between Nox2
and its partner in the complex p47phox (Rey et al., 2001). The
Nox2ds peptide, fused directly to the Tat CPP, has been shown to
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inhibit superoxide production in a variety of cell and tissue types in
response tomultiple stimuli. The peptide has beenused extensively
in many disease models including AngII-induced hypertension,
renovascular hypertension, and arterial balloon injury (reviewed
in Cifuentes-Pagano et al., 2012). For application in PE, we fused
the Nox2ds peptide to the CPP-ELP carrier (Bidwell and Raucher,
2009). The CPP-ELP carrier will increase the plasma half-life rela-
tive to the free peptide, and the use of the CPP will mediate uptake
of the polypeptide into target cells in the placenta or systemic vas-
culature. We are currently testing the ability of this polypeptide
to inhibit placental and/or vascular ROS production in our rat
models of PE.
CONCLUSION
The explosion of research into the etiology of preeclampsia has
provided a number of intriguing targets for therapeutic develop-
ment. The ideal scenario would be to understand the pathways
that lead to improper spiral artery remodeling and intervene
very early in pregnancy to prevent the improper remodeling.
However, in the absence of this knowledge and in the absence
of a concrete biomarker to predict which patients will develop
preeclampsia, this type of intervention is currently unrealistic.
In contrast, we now know of many of the molecular path-
ways that lead to the precipitation of the symptomatic phase
of preeclampsia. Our aim is to intervene during this symp-
tomatic phase and modulate these pathways of interest with
the goal of prolonging gestation and thereby improving fetal
outcomes. While small molecule therapeutics are one potential
method to affect these pathways, great care must be exercised in
their development, as unwanted and potentially harmful effects
to the fetus are possible. Peptide-based therapeutics, though an
active area of research in cancer therapy, also have potential
as therapeutics in cardiovascular disorders. However, free pep-
tides suffer from very rapid plasma clearance and susceptibility
to degradation in vivo. Our goal is to develop an appropri-
ate polymeric carrier that can be fused to either small molecule
drugs or to therapeutic peptides/proteins. By fusing these agents
to the carrier, they can be stabilized in the maternal circu-
lation and prevented from entering the fetal circulation. We
feel that the proposed therapeutic agents, or agents like them
that intervene in pathways of known importance in preeclamp-
sia (angiogenic factors, maternal inﬂammatory/autoimmune
response, and oxidative stress), have great promise as mater-
nally sequestered therapeutics. Future studies will explore the
therapeutic potential of these agents in the management of
preeclampsia.
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